Pyrimidines

"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.

Descriptor ID	D011743
MeSH Number(s)	D03.383.742
Concept/Terms	Pyrimidines Pyrimidines

Below are MeSH descriptors whose meaning is more general than "Pyrimidines".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyrimidines [D03.383.742]

Below are MeSH descriptors whose meaning is related to "Pyrimidines".

Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.

Bar chart showing 1494 publications over 28 distinct years, with a maximum of 93 publications in 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1992	1	0	1
1996	0	1	1
1997	1	0	1
1998	3	1	4
1999	0	1	1
2000	3	0	3
2001	6	9	15
2002	30	9	39
2003	50	14	64
2004	40	17	57
2005	31	14	45
2006	41	19	60
2007	55	37	92
2008	53	30	83
2009	66	23	89
2010	64	29	93
2011	56	36	92
2012	47	40	87
2013	47	41	88
2014	38	24	62
2015	41	38	79
2016	40	34	74
2017	40	40	80
2018	42	37	79
2019	36	38	74
2020	21	29	50
2021	30	22	52
2022	4	25	29

Below are the most recent publications written about "Pyrimidines" by people in Profiles.

Cantor E, Wierzbicki K, Tarapore RS, Ravi K, Thomas C, Cartaxo R, Nand Yadav V, Ravindran R, Bruzek AK, Wadden J, John V, May Babila C, Cummings JR, Rahman Kawakibi A, Ji S, Ramos J, Paul A, Walling D, Leonard M, Robertson P, Franson A, Mody R, Garton HJL, Venneti S, Odia Y, Kline C, Vitanza NA, Khatua S, Mueller S, Allen JE, Gardner SL, Koschmann C. Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. Neuro Oncol. 2022 08 01; 24(8):1366-1374.

View in: PubMed
Du C, Guan X, Yan J. Two-pore channel blockade by phosphoinositide kinase inhibitors YM201636 and PI-103 determined by a histidine residue near pore-entrance. Commun Biol. 2022 07 23; 5(1):738.

View in: PubMed
Mesa R, Harrison C, Oh ST, Gerds AT, Gupta V, Catalano J, Cervantes F, Devos T, Hus M, Kiladjian JJ, Lech-Maranda E, McLornan D, Vannucchi AM, Platzbecker U, Huang M, Strouse B, Klencke B, Verstovsek S. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia. 2022 09; 36(9):2261-2268.

View in: PubMed
Verstovsek S, Mesa R, Talpaz M, Kiladjian JJ, Harrison CN, Oh ST, Vannucchi AM, Rampal R, Scott BL, Buckley SA, Craig AR, Roman-Torres K, Mascarenhas JO. Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. Haematologica. 2022 07 01; 107(7):1599-1607.

View in: PubMed
Popat S, Liu SV, Scheuer N, Hsu GG, Lockhart A, Ramagopalan SV, Griesinger F, Subbiah V. Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer. Nat Commun. 2022 06 17; 13(1):3500.

View in: PubMed
Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Coutre SE, Dearden C, Grosicki S, McCarthy H, Li JY, Offner F, Moreno C, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia P. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022 06 14; 6(11):3440-3450.

View in: PubMed
Verstovsek S. Cases in the management of polycythemia vera: switching from hydroxyurea to ruxolitinib to resolve symptoms and improve quality of life. Clin Adv Hematol Oncol. 2022 06; 20 Suppl 11(6):1-12.

View in: PubMed
Doz F, van Tilburg CM, Geoerger B, Højgaard M, Øra I, Boni V, Capra M, Chisholm J, Chung HC, DuBois SG, Gallego-Melcon S, Gerber NU, Goto H, Grilley-Olson JE, Hansford JR, Hong DS, Italiano A, Kang HJ, Nysom K, Thorwarth A, Stefanowicz J, Tahara M, Ziegler DS, Gavrilovic IT, Norenberg R, Dima L, De La Cuesta E, Laetsch TW, Drilon A, Perreault S. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol. 2022 06 01; 24(6):997-1007.

View in: PubMed
Mangum R, Parsons DW. TRK inhibition for pediatric and adult central nervous system tumors: Early promise and future questions. Neuro Oncol. 2022 06 01; 24(6):1008-1009.

View in: PubMed
Pal SK, Somford DM, Grivas P, Sridhar SS, Gupta S, Bellmunt J, Sonpavde G, Fleming MT, Lerner SP, Loriot Y, Hoffman-Censits J, Valderrama BP, Andresen C, Schnabel MJ, Cole S, Daneshmand S. Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncol. 2022 Jul; 18(21):2599-2614.

View in: PubMed

People

Explore

Similar Concepts

Top Journals